Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22723270 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1GAAGRM2GRM3 | |
| SCHEMBL20190063 | 0.80 | GRM2 (0.37) | GRM2GRM3 | |
| SCHEMBL20201941 | 0.78 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1GAAGRM2 | |
| SCHEMBL765840 | 0.78 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1GAAGRM2 | |
| SCHEMBL17844798 | 0.77 | LMNA (0.47) | GRM2GRM3HIF1A | |
| Hydrochloric Acid SCHEMBL22723229 | 0.77 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1GAAGRM2 | |
| SCHEMBL22723275 | 0.77 | ADRB1 (0.43) | HIF1A | |
| SCHEMBL22723277 | 0.77 | ADRB1 (0.43) | HIF1A | |
| Hydrochloric Acid SCHEMBL22723226 | 0.77 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1GAAGRM2 | |
| SCHEMBL22772337 | 0.74 | SHBG (0.44) | ALDH1A1GAAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | SMN1; SMN2 3820/4885ALDH1A1 1207/4885GAA 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.